{"disease":{"id":"distributive-shock","name":"distributive shock","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"angiotensin","indication_name":"Septic or other distributive shock","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Angiotensin Ii","generic_name":"ANGIOTENSIN","company_name":"La Jolla Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Vasoconstrictor [EPC]","quality_score":46,"revenue":null,"mechanism":"Angiotensin II works by binding to its receptor, triggering a cascade of signals that ultimately lead to the constriction of blood vessels."},{"drug_id":"dopamine-hydrochloride","indication_name":"Improving hemodynamic status in distributive shock","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOPAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":11,"revenue":null,"mechanism":null},{"drug_id":"angiotensin","indication_name":"distributive shock","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Angiotensin Ii","generic_name":"ANGIOTENSIN","company_name":"La Jolla Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Vasoconstrictor [EPC]","quality_score":46,"revenue":null,"mechanism":"Angiotensin II works by binding to its receptor, triggering a cascade of signals that ultimately lead to the constriction of blood vessels."},{"drug_id":"isoproterenol","indication_name":"Improving hemodynamic status in distributive shock","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ISOPROTERENOL","company_name":"","drug_phase":"marketed","molecular_target":"beta-adrenergic receptors","drug_class":"Beta-adrenergic agonist","quality_score":80,"revenue":null,"mechanism":"Isoproterenol activates beta-adrenergic receptors without affecting alpha-adrenergic receptors."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03407287","title":"Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status","phase":"","overall_status":"TERMINATED","enrollment_count":180,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT04904562","title":"Angiotensin II for Distributive Shock","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT03431077","title":"A Study of LJPC-501 in Pediatric Patients With Hypotension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"La Jolla Pharmaceutical Company","has_results":false},{"nct_id":"NCT03245528","title":"Expanded Access for LJPC-501","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"La Jolla Pharmaceutical Company","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}